pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

slayback-pharma PRESS RELEASE ARCHIVE

Apr 26, 2023

Endo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Product in the U.S.

Jul 29, 2022

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify in the U.S.

Feb 4, 2021

Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla

Dec 18, 2020

Slayback Pharma announces FDA approval of Merzee, generic equivalent of Taytulla with a Competitive Generic Therapy (CGT) Designation

Dec 7, 2020

Slayback Pharma Appoints Dr Sumitra Pillai as Head of RandD

Sep 2, 2020

Slayback Pharma announces approval of Icatibant Injection 30 mg/3 ml (10 mg/ ml), generic equivalent of Firazyr.

Aug 17, 2020

Slayback Pharma Appoints Lori A. Hoffman as Head of Alliance Management

Jan 6, 2020

Slayback Pharma announces investment of $50 million by The Everstone Group

Dec 10, 2019

Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex™ 4 mcg/ mL

Mar 25, 2019

Slayback Pharma announces approval of Hydroxyprogesterone Caproate Injection, USP 250 mg/ 1 mL in a single-dose vial, generic equivalent of Makena Injection 250 mg/ 1 mL

Jan 21, 2019

Slayback Pharma announces launch of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena Injection 1,250 mg/ 5 mL multi-dose vial

Jan 2, 2019

Slayback Pharma announces FDA approval of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena Injection 1,250 mg/ 5 mL multi-dose vial

Jul 24, 2018

Slayback Pharma Appoints Dr Girish Jain as Head of Global RandD

Jul 16, 2018

Slayback Pharma Appoints Joan Janulis as Head of Global Regulatory Affairs

Jun 29, 2018

Ajay Singh of Slayback Pharma wins Ernst and Young's Entrepreneur Of The Year 2018 Award in Life Sciences Category in New Jersey

Apr 25, 2018

Ajay Singh of Slayback Pharma named Ernst and Young's Entrepreneur Of The Year 2018 Award Finalist in New Jersey

Jun 27, 2017

Slayback Pharma Appoints Patrick McIntosh as Head of Commercial Operations

Jan 5, 2017

Slayback Pharma Announces $60 Million in New Financing by KKR

Dec 23, 2016

Slayback Pharma announces the final approval and launch of Generic Zovirax (Acyclovir) Ointment 5%

Google Analytics Alternative